Latest Asx News

Sayona Mining has updated its timetable for the merger with Piedmont Lithium, conditional placement, and share consolidation, aiming to simplify and speed up the process pending shareholder approval.

Spheria Emerging Companies Limited has announced its highest-ever quarterly dividend of 3.6 cents per share, fully franked and payable in August 2025, reflecting strong long-term portfolio returns despite recent market volatility.

Rimfire Pacific Mining is advancing its position as a leading scandium explorer in Australia’s Fifield district, with plans for new Mineral Resource Estimates and a $3.5 million capital raise to fund drilling and exploration. Joint ventures with Golden Plains Resources have been reinstated, underpinning a strategic push in a critical mineral market facing supply constraints.

Rimfire Pacific Mining Limited has had its trading suspension lifted immediately following the release of its capital raising results, signaling renewed market activity.

Rimfire Pacific Mining has secured $3.5 million through a discounted share placement to accelerate scandium resource development across its NSW projects, signaling renewed momentum after arbitration setbacks.

Perpetual Resources Limited has requested a voluntary suspension of its shares on the ASX, pending important announcements related to exploration activities and a regulatory query. The suspension is expected to last until the market opens on July 24, 2025.

Fat Prophets Global Contrarian Fund Ltd announces a special fully franked dividend of AUD 0.05 per share, coupled with a dividend reinvestment plan offering a 2.5% discount. Key dates for investors are set for late August and September 2025.

Fat Prophets Global Contrarian Fund has announced a fully franked special dividend of 5 cents per share, reflecting strong investment performance. The dividend reinvestment plan offers shareholders a 2.5% discount on reinvested shares, signaling confidence in future growth.

Pengana International Equities Limited has announced a fully franked ordinary dividend of AUD 0.0135 per share for the quarter ending June 2025, with a Dividend Reinvestment Plan available to shareholders.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

Lake Resources has raised $2.1 million through its At-the-Market facility by issuing 65 million shares to Acuity Capital, while extending the agreement to 2031 to support its Kachi Project and working capital needs.